18,579 Shares in Blueprint Medicines Co. (NASDAQ:BPMC) Purchased by Bayesian Capital Management LP

Bayesian Capital Management LP bought a new stake in Blueprint Medicines Co. (NASDAQ:BPMC - Free Report) during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund bought 18,579 shares of the biotechnology company's stock, valued at approximately $1,620,000.

A number of other large investors have also added to or reduced their stakes in BPMC. Ameriprise Financial Inc. boosted its holdings in Blueprint Medicines by 4.2% in the fourth quarter. Ameriprise Financial Inc. now owns 338,115 shares of the biotechnology company's stock worth $29,489,000 after acquiring an additional 13,501 shares in the last quarter. Algert Global LLC grew its position in Blueprint Medicines by 21.6% during the 4th quarter. Algert Global LLC now owns 112,172 shares of the biotechnology company's stock worth $9,784,000 after purchasing an additional 19,936 shares during the last quarter. Alkeon Capital Management LLC increased its stake in Blueprint Medicines by 11.4% during the 4th quarter. Alkeon Capital Management LLC now owns 800,628 shares of the biotechnology company's stock valued at $69,831,000 after purchasing an additional 81,700 shares in the last quarter. Comerica Bank raised its holdings in shares of Blueprint Medicines by 411.5% in the fourth quarter. Comerica Bank now owns 13,115 shares of the biotechnology company's stock worth $1,144,000 after buying an additional 10,551 shares during the last quarter. Finally, PDT Partners LLC acquired a new stake in shares of Blueprint Medicines during the fourth quarter worth $270,000.

Wall Street Analyst Weigh In

BPMC has been the subject of a number of research reports. JPMorgan Chase & Co. lifted their price target on Blueprint Medicines from $126.00 to $129.00 and gave the stock an "overweight" rating in a research report on Tuesday, February 4th. Wolfe Research began coverage on Blueprint Medicines in a report on Tuesday, March 18th. They set an "outperform" rating for the company. StockNews.com upgraded shares of Blueprint Medicines from a "sell" rating to a "hold" rating in a report on Friday, May 2nd. Needham & Company LLC decreased their price objective on shares of Blueprint Medicines from $133.00 to $130.00 and set a "buy" rating for the company in a research note on Monday, April 28th. Finally, HC Wainwright reaffirmed a "buy" rating and issued a $135.00 price objective on shares of Blueprint Medicines in a report on Friday, May 2nd. Five analysts have rated the stock with a hold rating, thirteen have given a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, the company presently has an average rating of "Moderate Buy" and a consensus target price of $126.56.

Blueprint Medicines Price Performance

Shares of NASDAQ:BPMC traded down $1.02 during midday trading on Friday, reaching $97.74. 621,844 shares of the company's stock traded hands, compared to its average volume of 780,742. The company has a market cap of $6.31 billion, a P/E ratio of -90.50 and a beta of 0.83. The company has a fifty day simple moving average of $88.49 and a two-hundred day simple moving average of $93.81. The company has a debt-to-equity ratio of 1.15, a quick ratio of 2.80 and a current ratio of 2.85. Blueprint Medicines Co. has a 1 year low of $73.04 and a 1 year high of $121.90.

Blueprint Medicines (NASDAQ:BPMC - Get Free Report) last announced its earnings results on Thursday, May 1st. The biotechnology company reported ($0.74) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.42) by ($0.32). Blueprint Medicines had a negative net margin of 13.19% and a negative return on equity of 77.49%. The company had revenue of $149.41 million during the quarter, compared to analyst estimates of $158.31 million. During the same quarter last year, the business earned $1.40 EPS. The firm's revenue for the quarter was up 55.5% compared to the same quarter last year. Equities analysts predict that Blueprint Medicines Co. will post -1.28 EPS for the current fiscal year.

Insiders Place Their Bets

In other Blueprint Medicines news, COO Christina Rossi sold 2,274 shares of Blueprint Medicines stock in a transaction on Monday, March 24th. The shares were sold at an average price of $95.02, for a total transaction of $216,075.48. Following the sale, the chief operating officer now owns 69,266 shares of the company's stock, valued at $6,581,655.32. The trade was a 3.18 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, insider Ariel Hurley sold 3,203 shares of the stock in a transaction dated Monday, March 3rd. The shares were sold at an average price of $92.62, for a total transaction of $296,661.86. Following the completion of the sale, the insider now owns 18,270 shares of the company's stock, valued at $1,692,167.40. This trade represents a 14.92 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders sold 10,503 shares of company stock worth $1,027,931. Corporate insiders own 4.21% of the company's stock.

Blueprint Medicines Company Profile

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders.